 The metabolic syndrome which includes non-alcoholic fatty liver disease, obesity, and insulin resistance has responded to prebiotics in rodent trials; it is estimated that 20-30 of populations in developed countries have this disease. Parnell and Reimer have demonstrated that prebiotics oligofructose supplementation has the potential to promote weight loss and improve glucose regulation in overweight adults likely through suppressed ghrelin and enhanced PYY1. 